Atopic Dermatitis Clinical Trials Near You

Atopic dermatitis (eczema) trials in 2026 are riding a wave of innovation that began with dupilumab (Dupixent). JAK inhibitors — abrocitinib (Cibinqo), upadacitinib (Rinvoq), and baricitinib (Olumiant) — offer oral alternatives with rapid itch relief, often within days rather than the weeks required for biologics.

Next-generation biologics targeting OX40 ligand (amlitelimab, rocatinumab), IL-13 alone (tralokinumab, lebrikizumab, cendakimab), and IL-31 (nemolizumab for itch) are in Phase 2–3 trials. Nemolizumab is notable for rapid, dramatic pruritus reduction — addressing what patients often describe as the most debilitating AD symptom.

Topical JAK inhibitors (ruxolitinib cream) are approved for mild-to-moderate AD, with additional topical formulations in development. Tapinarof, a topical aryl hydrocarbon receptor (AhR) agonist approved for psoriasis, is also being studied for AD.

Microbiome-based therapies represent an emerging frontier: trials test whether applying beneficial bacteria (like Roseomonas mucosa) to the skin or modifying the gut microbiome can restore the dysfunctional skin barrier and reduce AD flares without immunosuppression.

Patient considerations: AD trials use standardized scoring systems (EASI, IGA, SCORAD) and often require a washout period from current medications. Photography of affected skin areas is standard. Many trials accept patients who have failed topical steroids — prior biologic experience may be required or excluded depending on the specific trial design.